SEC Form 4 · accession 0001127602-18-001563
BIOGEN INC. · BIIB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert W Pangia
Director
Period of report
Jan 9, 2018
Accepted (ET)
Jan 10, 2018 · 5:28 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875045
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 9, 2018 | M | 5,832 | $57.83 | A | 23,539 | D | |
| Common Stock | Jan 9, 2018 | S | 5,832 | $329.65 | D | 17,707 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $57.83 | Jan 9, 2018 | M | 5,832 | D | Jun 19, 2009 | Jun 18, 2018 | Common Stock | 5,832 | 0 | D |
Explanation of responses
- F1Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.
- F2This option was previously reported as covering 5,700 shares at an exercise price of $59.17 per share, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017.